



doximity

INVESTOR PRESENTATION

Fall 2024

LEGAL DISCLAIMER

This presentation and associated commentary may contain forward-looking statements, including statements regarding expectations of future results of operations or financial performance of Doximity, market size and growth opportunities, the calculation of certain of our key financial and operating metrics, capital expenditures, plans for future operations, competitive position, technological capabilities, and strategic relationships, general business conditions and the assumptions underlying those statements.

Any forward-looking statements contained in this presentation and associated commentary are based upon Doximity's historical performance and its plans, estimates and expectations as of the dates noted in this presentation, and are not a representation that such plans, estimates, or expectations have been or will be achieved. These forward-looking statements represent Doximity's expectations as of the dates noted in this presentation. You should not put undue reliance on any forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved, if at all. Subsequent events may cause these expectations to change, and Doximity disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including, but not limited to, those related to our business and financial performance, our ability to attract and retain customers, our ability to develop new products and services and enhance existing products and services, our ability to respond rapidly to emerging technology trends, our ability to execute on our business strategy, our ability to compete effectively and our ability to manage growth.

Additional risks and uncertainties that could affect Doximity's financial results are included under the captions, "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the company's filings with the Securities and Exchange Commission on Form 10-K and subsequent Form 10-Qs. These materials are available on our investor relations website at investors.doximity.com under the Financials section and on the SEC's website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Doximity makes with the SEC from time to time. In addition to financial information presented in accordance with U.S. generally accepted accounting principles ("GAAP"), this presentation and associated commentary may include certain non-GAAP financial measures (including on a forward-looking basis) such as Adjusted EBITDA and Free Cash Flow. Definitions and reconciliations of non-GAAP measures to their most directly comparable GAAP counterparts are available in our most recent Form 10-K or 10-Q on the company's investor relations website at investors.doximity.com.

THE DIGITAL PLATFORM FOR DOCTORS

Leading Network

80%+

of all U.S.
Physicians¹

Blue Chip Clients

20/20

Top Hospitals
and Health Systems
Top Pharmaceutical
Manufacturers³

Growth and Profit

17%

Subscription
Revenue Growth⁴

>600K

Workflow Unique
Active Providers²

116%

Net Revenue
Retention Rate⁴

53%

Adj. EBITDA
Margin⁴

1. As of 9/30/24.

2. For fiscal quarter ending 9/30/24.

3. Top 20 Pharmaceutical Manufacturers based on data from Evaluate, Top 20 hospitals based on U.S. News & World Report's Best Hospitals U.S. News Best Hospitals 2023-2024 Honor Roll.

4. For the trailing twelve month (TTM) period ending 9/30/24. Refer to appendix for definitions and non-GAAP reconciliations.

GLARING DAY-TO-DAY INEFFICIENCIES

80%

of US HC documents sent via
snail mail and fax¹

78%


of physicians **report burnout**, with health
IT as one of least satisfying factors²

1. Keeping it Together Issue Brief on Exchanging Medical Documentation CAQH Nov 2020. Does not include email.
2. 2018 Survey of America's Physicians Practice Patterns and Perspectives, The Physicians Foundation by Merritt Hawkins, September 2018.



BRINGING TECH TO MEDICINE

Inspired by enterprise tech



Note: These are not customers or partners, these are illustrative examples of premier enterprise tech solutions in their respective markets.

Purpose-built for healthcare



4.8 out of 5, 170K+ Ratings & Reviews¹




"This app has changed my professional life."


1. As of September 30, 2024.

PURPOSE BUILT FOR HEALTHCARE




Professional Network




Newsfeed



Productivity




ENGAGEMENT THROUGHOUT THE DAY



OUR COMMERCIAL SOLUTIONS

Marketing




Educate on Latest News & Treatments

Relevance and personalization drive Rx's & Referrals

1. Based on "Best in KLAS" Telehealth Video Conferencing Platform 2024

Hiring



Uncover Passive Candidates

Find specialized talent

Enterprise Workflow




Reduce No-Shows & Leakage

*#1 "Best in KLAS" Telehealth Video Conferencing
Hundreds of thousands of on-call schedules
AI driven clinical correspondence*


MARKETING SOLUTIONS

Largest Revenue Driver: Marketing Solutions



Leading Network

>73% of healthcare spend
is decided by Doctors¹



Subscription Pricing Model

1. Audience (e.g. specialty)
2. Number of audience members
3. Type and number of modules



Health
Systems

17:1 ROI²
LexisNexis



Pharma

> 11:1 ROI³
IQVIA

1. Center for Medicare & Medicaid Services, including categories of hospital care, physician & clinical services, retail prescription drugs, nursing care facilities & continuing care retirement communities, home health care, & durable medical equipment.


2. Our ROI studies are conducted using data from third party provider LexisNexis Risk Solutions for our health system customers. Median ROI as measured by third party claims data analysis of shared patient lift from new referring providers. As of September 2022.

3. Actual results vary based on therapy area, product price, product maturity, and the number of months over which the ROI was measured. As of March 2024.


LAND & EXPAND SALES MOTION

1

Land Initial Brands or Service Lines




Pharmaceutical Manufacturer




Health System

2

Expand to Add'l Brands or Service Lines




Pharmaceutical Manufacturer




Health System

3

Expand Number
& Type of
Modules Utilized




Pharmaceutical
Manufacturer




Health
System

CORE MODULE PORTFOLIO


We create
customized
packages for
customers



Long Form



Video




Short Form

WORKFLOW MODULES




Point of Care



Formulary

LARGE & GROWING TOTAL ADDRESSABLE MARKET



1. Pharmaceutical Marketing TAM represents total annual marketing spend by Pharmaceutical Manufacturers to Doctors. Source: IQVIA 2019 US ChannelDynamics and Kantar Media Intelligence, US Healthcare Ad Spend


2. Health System Marketing and Staffing TAM represents Hospital Marketing Spend, Revenue Opportunity from Locum Tenens solutions and Permanent Staffing solutions. Source: BIA Advisory Services, GVR, Kaiser Family Foundation and the AAPPR In-House Physician and Provider Recruitment benchmarking

3. Telehealth TAM represents revenue opportunity from Telehealth sales to care locations and individuals. Source: IBISWorld

RX BRAND OPPORTUNITY


Doximity Brand Penetration \$100M+ US Sales¹

% of Brands in Each Cohort




Doximity Brand Penetration <\$100M US Sales²

% of Brands in Each Cohort



Estimated Doximity Share of HCP Marketing Budgets by Brand³

% of Brands in Each Cohort



1. As of March 31, 2024. # of brands with \$100m+ in US sales (based on data from Evaluate Pharma) where Doximity has revenue.

2. As of March 31, 2024. # of brands between \$1m to \$100m in US sales (based on data from Evaluate Pharma) where Doximity has revenue.

3. As of March 31, 2024. Estimated Doximity Share of HCP Marketing Budgets is calculated by assuming a certain percent of a brand's US Sales is spent on HCP marketing. We then take Doximity's revenue for that brand and divide it by our estimate of its HCP marketing budget. This is looking at Doximity Share of HCP Marketing Budgets for the cohort of brands with \$1m+ in US Sales.

Q2 KEY METRICS

LAND

Number of Customers w/ \$500K+ of Revenue¹

103 \$500K+
+ 12% y/y

&

EXPAND



Net Revenue Retention²

116%
Total Company

Top 20
Customers
124%

1. Refer to appendix for the definition of customers with trailing 12-month subscription revenue greater than \$500,000.
2. Refer to appendix for the definition of Net Revenue Retention.

ATTRACTIVE REVENUE GROWTH & MARGIN PROFILE



FOUNDER-LED, MISSION DRIVEN



Jeff Tangney
CEO & Co-Founder



Dr. Nate Gross
CSO & Co-Founder



Anna Bryson
CFO



Lisa Greenbaum
CCO



Jey Balachandran
CTO



Amit Phull, MD
Chief Physician Experience Officer




Ben Greenberg
SVP Commercial Products



Joel Davis
SVP Product



Jennifer Chaloemtiarana
General Counsel



COMPANY HIGHLIGHTS

- 1 Leading digital platform for doctors
- 2 Powerful network effects
- 3 Sustainable revenue growth & profitability
- 4 Veteran vertical team
- 5 Massive near-term market opportunity fueled by shift to digital

APPENDIX: NON-GAAP FINANCIAL MEASURES

To supplement our condensed consolidated financial statements, which are prepared and presented in accordance with accounting principles generally accepted in the United States ("GAAP"), the Company uses the following non-GAAP measures of financial performance:

Non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating income, non-GAAP net income, non-GAAP net income margin, and non-GAAP basic and diluted net income per common share: We exclude the effect of stock-based compensation expense, amortization of acquired intangible assets, restructuring and impairment charge, change in fair value of contingent earn-out consideration liability, and acquisition and other related expenses from non-GAAP gross profit, non-GAAP gross margin and non-GAAP operating income. Non-GAAP net income and non-GAAP net income margin are further adjusted for estimated income tax on such adjustments. We calculate income taxes on the adjustments by applying an estimated annual effective tax rate to the adjustments. Non-GAAP basic and diluted net income per common share is non-GAAP net income attributable to common stockholders divided by the weighted average number of shares. For both basic and diluted non-GAAP net income per share, the weighted average shares we use in computing non-GAAP net income per share is equal to our GAAP weighted average shares. Non-GAAP gross margin represents non-GAAP gross profit as a percentage of revenue and non-GAAP net income margin represents non-GAAP net income as a percentage of revenue.

Adjusted EBITDA and adjusted EBITDA margin: We define adjusted EBITDA as net income before interest, income taxes, depreciation, and amortization, and as further adjusted for acquisition and other related expenses, stock-based compensation expense, restructuring and impairment charge, change in fair value of contingent earn-out consideration liability, and other income, net. Net income margin represents net income as a percentage of revenue and adjusted EBITDA margin represents adjusted EBITDA as a percentage of revenue.

Free cash flow: We calculate free cash flow as cash flow from operating activities less purchases of property and equipment and internal-use software development costs.

We use these non-GAAP financial measures internally for financial and operational decision-making purposes and as a means to evaluate period-to-period comparisons. Non-GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable GAAP financial measures and should be read only in conjunction with our condensed consolidated financial statements prepared in accordance with GAAP. Our presentation of non-GAAP financial measures may not be comparable to similar measures used by other companies. We encourage investors to carefully consider our results under GAAP, as well as our supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand our business. Please see the tables included at the end of this release for the reconciliation of GAAP to non-GAAP results.

Key Business Metrics

Net revenue retention rate: Net revenue retention rate is calculated by taking the trailing 12-month ("TTM") subscription-based revenue from our customers that had revenue in the prior TTM period and dividing that by the total subscription-based revenue for the prior TTM period. For the purposes of this calculation, subscription revenue excludes subscriptions for individuals and small practices and other non-recurring items. Our net revenue retention rate compares our subscription revenue from the same set of customers across comparable periods, and reflects customer renewals, expansion, contraction, and churn. Our net revenue retention rate is directly tied to our revenue growth rate and thus fluctuates as that growth rate fluctuates.

Customers with trailing 12-month subscription revenue greater than \$500,000: The number of customers with TTM subscription revenue greater than \$500,000 is a key indicator of the scale of our business, and is calculated by counting the number of customers that contributed more than \$500,000 in subscription revenue in the TTM period. Our customer count is subject to adjustments for acquisitions, consolidations, spin-offs, and other market activity, and we present our total customer count for historical periods reflecting these adjustments.

APPENDIX: ADJUSTED EBITDA & MARGIN NON-GAAP RECONCILIATION

	Year Ended March 31,					TTM
	2020	2021	2022	2023	2024	Q2 FY25
	(in thousands)					(in thousands)
Net Income	\$29,737	\$50,210	\$154,783	\$112,818	\$147,582	\$174,105
Adjustments:						
Acquisition and other related expenses	1,158	496	254	30	—	—
Stock-based compensation	2,353	7,252	31,442	47,834	47,430	58,586
Depreciation and amortization	900	3,702	5,040	10,283	10,265	10,232
Provision for (benefit from) income taxes	(6,223)	7,559	(40,778)	20,338	37,620	52,220
Restructuring and impairment charge	—	—	—	—	7,936	2,304
Change in fair value of contingent earn-out consideration liability	—	—	—	728	951	1,058
Other income, net	(1,351)	(4,466)	(469)	(8,048)	(21,324)	(26,727)
Adjusted EBITDA	\$26,574	\$64,753	\$150,272	\$183,983	\$230,460	\$271,778
Revenue	\$116,388	\$206,897	\$343,548	\$419,052	\$475,422	\$516,849
Adjusted EBITDA Margin	23%	31%	44%	44%	48%	53%